Skip to main content

Advertisement

SpringerLink
Log in

A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Drug-induced nephrotoxicity is one of the most common side effects of medications and accounts for about 20 % of hospital admissions for acute kidney injury (AKI). Some possible pharmacologic mechanisms of pentoxifylline (PTX) that suggest it as a candidate to ameliorate AKI include interaction at the level of the adenosine receptors, increase in erythrocyte deformability, stimulation of vasodilatory prostaglandins production and prevention of vascular congestion, and suppression of tumor necrosis factor alpha (TNF-α) and apoptosis. This manuscript reviews all clinical and animal studies on the use of PTX as a renoprotective agent against a number of nephrotoxic drugs.

Methods

Data were collected by searching MEDLINE, PubMed, Scopus, Cochrane central register of controlled trials, and Cochrane database systematic reviews. Key words used as search terms were pentoxifylline, nephroprotective, renoprotective, drug-induced renal diseases, drug-induced nephrotoxicity, drug-induced renal toxicity, and drug-induced nephropathy. This search was performed without time limitation.

Results and conclusion

Most greatest number of studies and human clinical trials on the renoprotective effect of PTX against drug-induced nephrotoxicity involves cyclosporine (Cyc). It seems that despite encouraging results from animal studies, there is insufficient evidence to support the renoprotective effect of PTX against Cyc-induced nephrotoxicity in humans. Although some available animal studies show protective effects of PTX against renal toxicity of some antimicrobial and cytotoxic agents, designing clinical trials to approve these nephroprotective effects requires prior confirmation of no reducing antimicrobial or antitumor action of these medications by PTX.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nolin TD, Himmelfarb J (2010) Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol 196:111–130

    Article  PubMed  CAS  Google Scholar 

  2. Samlaska CP, Winfield EA (1994) Pentoxifylline. J Am Acad Dermatol 30:603–621

    Article  PubMed  CAS  Google Scholar 

  3. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M (2010) Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 34:10–16

    PubMed  CAS  Google Scholar 

  4. Noel C, Copin MC, Hazzan M, Labalette M, Susen S, Lelievre G, Dessaint JP (2000) Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules. Transplantation 69:1102–1107

    Article  PubMed  CAS  Google Scholar 

  5. Savic V, Vlahovic P, Djordjevic V, Mitic-Zlatkovic M, Avramovic V, Stefanovic V (2002) Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure. Pathol Biol 50:599–607

    Article  PubMed  CAS  Google Scholar 

  6. Heystek HC, Thierry AC, Soulard P, Moulon C (2003) Phosphodiestrase 4 inhibitors reduce humen dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 15:827–835

    Article  PubMed  CAS  Google Scholar 

  7. Dousa TP (1998) Signaling role of PDE isozymes in pathobiology of glomelurar mesangial cells. Studies in vitro and in vivo. Cell Biochem Biophys 29:19–34

    Article  PubMed  CAS  Google Scholar 

  8. Prasad K, Lee P (2007) Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 192:313–322

    Article  PubMed  CAS  Google Scholar 

  9. Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, Abdollahi M (2011) A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharm Sci 14:128–137

    PubMed  CAS  Google Scholar 

  10. Safarinejad MR (2011) Effect of pentoxifylline on semen parameters, reproductive hormones, and seminal plasma antioxidant capacity in men with idiopathic infertility: a randomized double-blind placebo-controlled study. Int Urol Nephrol 43:315–328

    Article  PubMed  CAS  Google Scholar 

  11. Berens KL, Luke DR (1990) Pentoxifylline in the isolated perfused rat kidney. Transplantation 49:876–879

    Article  PubMed  CAS  Google Scholar 

  12. Albornoz LE, Sanchez SB, Bandi JC, Canteros G, de las Heras M, Mastai RC (1997) Pentoxifylline reduces nephrotoxicity associated with cyclosporine in the rat by its rheological properties. Transplantation 64:1404–1407

    Article  PubMed  CAS  Google Scholar 

  13. Stojiljkovic N, Veljkovic S, Mihailovic D, Stoiljkovic M, Radenkovic M, Rankovic G, Randjelovic P (2009) Protective effects of pentoxifylline treatment on gentamicin-induced nephrotoxicity in rats. Ren Fail 31:54–61

    Article  PubMed  CAS  Google Scholar 

  14. Krysztopik RJ, Matheson PJ, Spain DA, Garrison RN, Wilson MA (2000) Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res 93:75–81

    Article  PubMed  CAS  Google Scholar 

  15. Usta Y, Ismailoglu UB, Bakkaloglu A, Orhan D, Besbas N, Sahin-Erdemli I, Ozen S (2004) Effects of pentoxifylline in Adriamycin-induced renal disease in rats. Pediatr Nephrol 19:840–843

    Article  PubMed  Google Scholar 

  16. Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant Epub 2012 Jan 4

  17. Danovich GM (2010) Immunosuppressive medications and protocols for kidney transplantation. In: Danovich GM (ed) Hand book of kidney transplantation. Lippincott Williams and Wilkins, a Wolters Kluwer Health business, Philadelphia, 90

    Google Scholar 

  18. Brunner LJ, Vadiei K, Iyer LV, Luke DR (1989) Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. Ren Fail 11:97–104

    Article  PubMed  CAS  Google Scholar 

  19. Bennett WM, Elzinga LW, Porter GA, Rosen S (1992) The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity. Transplantation 54:1118–1120

    Article  PubMed  CAS  Google Scholar 

  20. Carrier M, Perrault LP, Tronc F, Stewart DJ, Pelletier CL (1993) Pentoxifylline decreases cyclosporine-induced renal endothelin release and vasoconstriction. Ann Thorac Surg 55:490–492

    Article  PubMed  CAS  Google Scholar 

  21. Ates E, Sharma P, Erkasap S, Talbot D, Ihtiyar E, Yasar B, Kiper H (1996) Cyclosporine nephrotoxicity in the ischemic kidney and the protective effect of pentoxifylline—a study in the rat. Transplantation 62:864–867

    Article  PubMed  CAS  Google Scholar 

  22. Potier M, Aparicio M, Cambar J (1997) Protective effect of three xanthine derivatives (theophylline, caffeine and pentoxifylline) against the cyclosporin A-induced glomerular contraction in isolated glomeruli and cultured mesangialcells. Nephron 77:427–434 (Abstract was used)

    Article  PubMed  CAS  Google Scholar 

  23. Kaputlu I, Sadan G, Karayalçin B, Boz A (1997) Beneficial effects of pentoxifylline on cyclosporine-induced nephrotoxicity. Clin Exp Pharmacol Physiol 24:365–369

    Article  PubMed  CAS  Google Scholar 

  24. Shifow AA, Naidu MU, Kumar KV, Prayag A, Ratnakar KS (2000) Effect of pentoxifylline on cyclosporine-induced nephrotoxicity in rats. Indian J Exp Biol 38:347–352 (Abstract was used)

    PubMed  CAS  Google Scholar 

  25. Bianco JA, Almgren J, Kern DL, Ballard B, Roark K, Andrews F, Nemunaitis J, Shields T, Singer JW (1991) Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Results of a pilot study. Transplantation 51:925–927

    Article  PubMed  CAS  Google Scholar 

  26. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW (1991) Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78:1205–1211

    PubMed  CAS  Google Scholar 

  27. Peri A, Lang I, Gonzalez-Cabello R, Filep J, Nekam K, Gergely P, Feher J (1986) Indomethicin abrogates the suppression by cyclosporine A of lectin-dependent cell-mediated cytotoxicity to HEp-2 cells. Immunopharmacology 11:39–45

    Article  Google Scholar 

  28. Hang J, Thompson P, Beutler B (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separates points in the signaling pathway. J Exp Med 172:391–394

    Article  Google Scholar 

  29. Kalhs P, Lechner K, Stockschläder M, Krüger W, Peters S, Zander A (1992) Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients. Blood 80:2683–2684

    PubMed  CAS  Google Scholar 

  30. Stockschläder M, Kalhs P, Peters S, Zeller W, Krüger W, Kabisch H, Lechner K, Zander A (1993) Intravenous pentoxfylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 12:357–362

    PubMed  Google Scholar 

  31. López J, Cancelas JA, Valiño JM, García-Laraña J, Sastre JL, Pérez-Oteyza J, Cerveró C, García-Avello A, Cabezudo E, Arranz MI (1994) Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation. Med Clin 102:485–488

    Google Scholar 

  32. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, Laurent G, Pris J (1993) Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 82:732–736

    PubMed  CAS  Google Scholar 

  33. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, Bensinger WI, Bowden RA, McDonald GB, Schubert M (1993) A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 82:2025–2030

    PubMed  CAS  Google Scholar 

  34. White JR Jr, Rockwood T, Wilson D, Bettesworth L, Icenogle T (1994) The effects of pentoxifylline on the prevention of cyclosporine-induced nephrotoxicity in cardiac transplant patients. Clin Ther 16:673–679 (Abstract was used)

    PubMed  Google Scholar 

  35. Carrier M, Pelletier GB, White M, Bois D, Pelletier LC (1996) Effect of pentoxifylline on renal toxicity of cyclosporine: results of a clinical trial after heart transplantation. J Heart Lung Transplant 15:1179–1183

    PubMed  CAS  Google Scholar 

  36. Frantz RP, Edwards BS, Olson LJ, Schwab MK, Adams TF, Textor SC, Daly RC, McGregor CG, Rodeheffer RJ (1997) Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial. Transplantation 63:1607–1610

    Article  PubMed  CAS  Google Scholar 

  37. Königsrainer A, Aichberger C, Riedmann B, Steurer W, Ofner D, Margreiter R (1995) Pentoxifylline as an adjunct to cyclosporine-based immunosuppression does not improve the outcome of renal transplantation. Transplant Proc 27:1062–1063 (Abstract was used)

    PubMed  Google Scholar 

  38. Noel C, Hazzan M, Labalette M, Coppin MC, Jude B, Dessaint JP, Lelievre G (1998) Improvement in the outcome of rejection with pentoxifylline in renal transplantation: a randomized controlled trial. Transplantation 65:385–389

    Article  PubMed  CAS  Google Scholar 

  39. Kaynar K, Ersoz S, Aliyazicioglu R, Uzun A, Ulusoy S, Al S, Ozkan G, Cansız M (2012) Is there any way to protect from tacrolimus-induced renal and pancreas injury? Clin Transplant. doi:10.1111/j.1399-0012.2012.01603.x [Epub ahead of print]

  40. Deray G (2002) Amphotericin B, nephrotoxicity. J Antibicrob Chem 49:37–41

    Article  CAS  Google Scholar 

  41. Laniado-Laborin R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26:223–227

    Article  PubMed  Google Scholar 

  42. Sullivan GW, Carper HT, Mandell GL (1992) Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro. Antimicrob Agents Chemother 36:408–416

    Article  PubMed  CAS  Google Scholar 

  43. Luke DR, Wasan KM, McQueen TJ, Lopez-Berestein G (1990) Enhancement of the treatment of experimental candidiasis with vascular decongestants. J Infect Dis 162:211–214

    Article  PubMed  CAS  Google Scholar 

  44. Wasan KM, Vadiei K, Lopez-Berestein G, Verani RR, Luke DR (1990) Pentoxifylline in amphotericin B toxicity rat model. Antimicrob Agents Chemother 34:241–244

    Article  PubMed  CAS  Google Scholar 

  45. Kenedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED (1983) Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 35:211–215

    Article  Google Scholar 

  46. Balakumar P, Rohilla A, Thangathirupathi A (2010) Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res 62:179–186

    Article  PubMed  CAS  Google Scholar 

  47. Mimgeot-Leclercq MP, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43:1003–1012

    Google Scholar 

  48. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, Britti D, De Sarro A, Pierpaoli S, Caputi A, Masini E, Salvemini D (2002) A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 450:67–76

    Article  PubMed  CAS  Google Scholar 

  49. Shah SV (1984) Effect of enzymatically generated reactive oxygen metabolites on the cyclic nucleotide content in isolated rat glomeruli. J Clin Invest 74:393–401

    Article  PubMed  CAS  Google Scholar 

  50. Stojiljković N, Veljković S, Mihailović D, Stoiljković M, Ranković G, Jovanović I, Randjelović P (2009) Pentoxifylline ameliorates glomerular basement membrane ultrastructural changes caused by gentamicin administration in rats. Bosn J Basic Med Sci 9:239–244

    PubMed  Google Scholar 

  51. Ozer MK, Asci H, Oncu M, Yesilot S, Savran M, Bayram D, Cicek E (2009) Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats. Ren Fail 31:134–139

    Article  PubMed  CAS  Google Scholar 

  52. Veiga JPR, Wolf ER, Sampaio RNR, Marsden PD (1983) Renal tubular dysfunction in patients with muco-cutaneous leishmaniasis treated with pentavalent antimonials. Lancet 2:569

    Article  PubMed  CAS  Google Scholar 

  53. Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPR, Costa JLM, Lianos-Cuentas EA (1985) High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. AmJTrop Med Hyg 34:710–713

    CAS  Google Scholar 

  54. Chulay JD, Fleckenstein L, Smith DH (1988) Pharmacokinetics of antimony during treatment of visceral leshmaniasis with sodium stibigluconate or meglumine antimonite. Trans R Soc Trop Med Hyg 82:69–72

    Article  PubMed  CAS  Google Scholar 

  55. deMoura FJ, Leal PP, de Souza FR, Muniz-Junqueira MI, Veiga JP (2008) Pentoxifylline prevents the meglumineantimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride. Toxicology 243:66–74

    Article  Google Scholar 

  56. Gagliardi AR, Veiga JP, Rosa TT, Marsden PD (1985) Pentavalent antimonial inhibition of the osmotic effect of oxytocin on the isolated toad bladder. Braz J Med Biol Res 18:567–571 (Abstract was used)

    PubMed  Google Scholar 

  57. Sleijfer DT, Meijer S, Mulder NH (1985) Cisplatin: a review of clinical applications and renal toxicity. Pharm Weekbl Sci 7:237–244

    Article  PubMed  CAS  Google Scholar 

  58. Ferriere JM, Piechaud T, Gaston R, Brucher P, Grenier N, Leguillou M (1988) Cisplatin-based chemotherapy in the treatment of advanced stage tumors of bladder. Ann Urol Paris 22:442–445

    PubMed  CAS  Google Scholar 

  59. Jose B, Desmukh Y, Sharma SC (1984) Local control in advanced head and neck cancer by combined modalities of treatment. J Surg Oncol 26:230–232

    Article  PubMed  CAS  Google Scholar 

  60. Arany I, Safirstein RL (2010) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464

    Article  Google Scholar 

  61. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins 2:2490–2518

    Article  PubMed  CAS  Google Scholar 

  62. Berens KL, Luke DR (1990) Pentoxifylline in the isolated perfused rat kidney. Transplanation 49:876–879

    Article  CAS  Google Scholar 

  63. Biolo G, Ciocchi B, Bosutti A, Situlin R, Toigo G, Guarnieri G (2002) Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. Am J Kidney Dis 40:1162–1172

    Article  PubMed  CAS  Google Scholar 

  64. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in Cisplatin nephrotoxicity. J Clin Invest 110:743–745

    Google Scholar 

  65. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ (1999) Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56:932–943

    Article  PubMed  CAS  Google Scholar 

  66. Luke DR, Vadiei K, Lopez-Berestein G (1992) Role of vascular congestion in Cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 7:1–7

    PubMed  CAS  Google Scholar 

  67. Kim YK, Choi TR, Kwon CH, Kim JH, Woo JS, Jung JS (2003) Beneficial effect of pentoxifylline on Cisplatin-induced acute renal failure in rabbits. Ren Fail 25:909–922

    Article  PubMed  CAS  Google Scholar 

  68. Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R, Lupattelli G, Santambrogio L, Mannarino E (1991) Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. Eur J Clin Pharmacol 41:511–515

    Article  PubMed  CAS  Google Scholar 

  69. Franzini E, Sellak H, Hakim J, Pasquier C (1993) Oxidative damage to lysozyme by the hydroxyl radical: comparative effects of scavengers. Biochim Biophys Acta 1203:11–17

    Article  PubMed  CAS  Google Scholar 

  70. Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50–97

    Article  PubMed  CAS  Google Scholar 

  71. Kruidering M, de Walter BV, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells, mitochondrial dysfunction by inhibition of complex I to IV of the respiratory chain. J Pharmacol Ezp Ther 280:638–649

    CAS  Google Scholar 

  72. Saad SY, Najjar TA, Alashari M (2004) Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in Cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol 31:862–867

    Article  PubMed  CAS  Google Scholar 

  73. Malarkodi KP, Balachandar AV, Varlakshmi P (2003) The influence of lipoic acid on adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem 247:139–145

    Article  PubMed  CAS  Google Scholar 

  74. Ozen S, Usta Y, Sahin-Erdemli I, Orhan D, Gumusel B, Yang B, Gursoy Y, Tulunary O, Dalkara T, Bakkaloglu A, El-Nahas M (2001) Association of nitric oxide production and apoptosis in a model of experimental nephropathy. Nephrol Dial Transplant 16:32–38

    Article  PubMed  CAS  Google Scholar 

  75. Gomez-Chiarri M, Ortiz A, Lerma JL, Lopez-Armada MJ, Mampaso F, Gonzalez E, Egido J (1994) Involvement of tumornecrosis factor and platelet activating factor in the pathogenesis of experimental nephrosis in rats. Lab Invest 70:449–459

    PubMed  CAS  Google Scholar 

  76. Izzedine H, Launary-Vacher V, Karie S (2005) Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 64:315–319

    PubMed  CAS  Google Scholar 

  77. Djerassi I (1975) High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: back ground and rational. Cancer Chemother Rep 6:3–6

    Google Scholar 

  78. Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A (2011) Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci 15:1003–1009

    PubMed  CAS  Google Scholar 

  79. Gleeson TG, Bulugahapitiya S (2004) Contrast-induced nephropathy. AJR Am J Roentgenol 183:1673–1689

    Article  PubMed  Google Scholar 

  80. Roozbeh J, Hamidian Jahromi A, Sharifian M, Pakfetrat M, Afshariani R (2008) Protective effect of pentoxifylline on contrast induced nephropathy. Saudi J Kidney Dis Transpl 19:985–986

    PubMed  Google Scholar 

  81. Firouzi A, Eshraghi A, Shakerian F, Sanati HR, Salehi N, Zahedmehr A, Kiani R, Madani M, Pedarzadeh A (2011) Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients. Int Urol Nephrol [Epub ahead of print]

  82. http://clinicaltrial.gov/ct2/show/NCT01144091

  83. http://clinicaltrial.gov/ct2/show/NCT01469624

  84. Singh NP, Ganguli A, Prakash A (2003) Drug-induced kidney diseases. J Assoc Physicians India 51:970–979

    PubMed  CAS  Google Scholar 

  85. Bianco JA, Singer JW (1992) Response to: Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients. Blood 80:2683–2684

    Google Scholar 

Download references

Competing interest

None.

Author information

Authors and Affiliations

  1. Tehran University of Medical Sciences, Tehran, Iran

    Zahra Nasiri-Toosi

  2. Faculty of Pharmacy, Tehran University of Medical Sciences, P.O. Box: 14155/6451, 1417614411, Tehran, Iran

    Simin Dashti-Khavidaki & Hossein Khalili

  3. Nephrology Research Center, Tehran University of Medical Sciences, P.O. Box: 14155/6451, 1417614411, Tehran, Iran

    Simin Dashti-Khavidaki & Mahboob Lessan-Pezeshki

Authors
  1. Zahra Nasiri-Toosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simin Dashti-Khavidaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Khalili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mahboob Lessan-Pezeshki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simin Dashti-Khavidaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nasiri-Toosi, Z., Dashti-Khavidaki, S., Khalili, H. et al. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 69, 1057–1073 (2013). https://doi.org/10.1007/s00228-012-1452-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1452-x

Keywords

Search

Navigation